1. Show article details.

    Gen Z investors shift focus from 'meme-stocks' to the 'metaverse,' report shows

    Reuters – 9:00 AM ET 01/14/2022

    Enthusiasm around "meme stocks" has eased for young investors a year on from the GameStop Corp (GME) trading frenzy, with Gen Z's attention shifting to companies in areas like electric vehicles and the "metaverse," according to a report released on Friday.

  2. Show article details.

    BRIEF-Covaxin™ (Bbv152) Booster Shown To Neutralize Both Omicron And Delta Variants Of SARS-COV-2

    Reuters – 9:17 AM ET 01/12/2022

    Ocugen Inc (OCGN): * COVAXIN™ BOOSTER SHOWN TO NEUTRALIZE BOTH OMICRON AND DELTA VARIANTS OF SARS-COV-2. * Ocugen Inc (OCGN) - 100% OF TEST SERUM SAMPLES SHOWED NEUTRALIZATION OF DELTA VARIANT. * Ocugen Inc (OCGN) - MORE THAN 90% OF SERUM SAMPLES SHOWED NEUTRALIZATION OF OMICRON VARIANT.

  3. Show article details.

    India's Bharat Biotech says Covaxin booster shot neutralises Omicron

    Reuters – 7:45 AM ET 01/12/2022

    India's Bharat Biotech said on Wednesday a booster shot of its Covaxin COVID-19 vaccine administered six months after the last of two doses neutralises both the Omicron and Delta variants of the coronavirus. The study was conducted at the Emory Vaccine Center in Atlanta based on blood serum collected from 13 individuals, 28 days after their booster shot.

  4. Show article details.

    COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

    GlobeNewswire – 6:43 AM ET 01/12/2022

    MALVERN, Pa., Jan. 12, 2022 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, and its partner, Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced results from a study conducted at Emory University demonstrating that sera from subjects who rece...

  5. Show article details.

    COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

    GlobeNewswire – 6:27 PM ET 01/08/2022

    MALVERN, Pa., Jan. 08, 2022 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that its partner, Bharat Biotech, posted positive results from a Phase 2 analysis of the vaccine candidate, COVAXIN™, in participants ages 12-64, receiving a booster dose six months following a second dose on the pre-print se...

  6. Show article details.

    Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference

    GlobeNewswire – 6:03 PM ET 01/06/2022

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in H.C. Wainwright’s Bioconnect Conference taking place next week on January 10-13, 2022.

  7. Show article details.

    BRIEF-Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity And Safety Data From Covaxin™ (Bbv152), Covid-19 Candidate Vaccine, In Children 2 - 18 Years

    Reuters – 10:03 AM ET 12/30/2021

    Ocugen Inc (OCGN): * OCUGEN PARTNER, BHARAT BIOTECH, ANNOUNCES POSITIVE IMMUNOGENICITY AND SAFETY DATA FROM COVAXIN™, COVID-19 CANDIDATE VACCINE, IN CHILDREN 2 - 18 YEARS. * Ocugen Inc (OCGN) - ADVERSE EVENTS WERE PRIMARILY MILD, AND NO SERIOUS ADVERSE EVENTS WERE NOTED.

  8. Show article details.

    Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

    GlobeNewswire – 9:59 AM ET 12/30/2021

    MALVERN, Pa., Dec. 30, 2021 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ , in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favor...

  9. Show article details.

    Ocugen, Inc. Announces Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:32 PM ET 12/20/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen (OCGN) approved the grant of stock options to purchase an aggregate of 6,750 shares of its common stock and restricted stock units...

  10. Show article details.

    BRIEF-Ocugen Says Board Member To Resign

    Reuters – 5:27 PM ET 12/15/2021

    Ocugen Inc (OCGN): * OCUGEN (OCGN) - ON DEC 9, 2021, SUHA TASPOLATOGLU, MEMBER OF BOARD OF CO, NOTIFIED CO OF HIS INTENTION TO RESIGN FROM HIS POSITION AS MEMBER OF BOARD. * Ocugen Inc (OCGN) - BOARD DECREASED SIZE OF BOARD FROM EIGHT TO SEVEN MEMBERS. * OCUGEN (OCGN) - TASPOLATOGLU'S DECISION TO RESIGN WAS DUE TO PERSONAL ADMINISTRATIVE CHALLENGES POSED BY COVID-19 PANDEMIC Further company coverage:

  11. Show article details.

    BRIEF-New Data Suggest Covaxin™ (Bbv152) Vaccine Candidate Generates Robust Immune Memory To Covid-19 And Variants Of Concern

    Reuters – 9:34 AM ET 12/15/2021

    Ocugen Inc (OCGN): * NEW DATA SUGGEST COVAXIN™ VACCINE CANDIDATE GENERATES ROBUST IMMUNE MEMORY TO COVID-19 AND VARIANTS OF CONCERN FOR AT LEAST SIX MONTHS AFTER VACCINATION. * Ocugen Inc (OCGN) - LEVEL OF VACCINE-INDUCED SPIKE AND NUCLEOPROTEIN ANTIBODIES TITERS DEMONSTRATED TO BE COMPARABLE TO THAT FOLLOWING NATURAL INFECTION.

  12. Show article details.

    New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination

    GlobeNewswire – 6:46 AM ET 12/15/2021

    MALVERN, Pa., Dec. 15, 2021 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that data analyzing immune response following two doses of the vaccine candidate, COVAXIN™, from a third-party study were published on the preprint server, medRxiv.

  13. Show article details.

    BRIEF-Ocugen Inc Announces FDA Acceptance Of IND Application To Initiate Phase 1/2 Clinical Trial For Gene Therapy Candidate OCU400 To Treat Inherited Retinal Degeneration

    Reuters – 7:38 AM ET 12/09/2021

    Ocugen Inc (OCGN): * OCUGEN, INC. ANNOUNCES U.S. FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE A PHASE 1/2 CLINICAL TRIAL FOR GENE THERAPY CANDIDATE OCU400 TO TREAT INHERITED RETINAL DEGENERATION. * Ocugen Inc (OCGN) - TRIAL TO START IN Q1 2022 WILL ENROLL PATIENTS WITH MUTATIONS IN NR2E3 OR RHO GENES Source text for Eikon: Further company coverage:

  14. Show article details.

    Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

    GlobeNewswire – 7:28 AM ET 12/09/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, announced that the U.S. Food and Drug Administration has accepted the company’s Investigational New Drug application to initiate a first-in-human clinical trial of OCU400, a modifier gene therapy candidate for the...

  15. Show article details.

    BRIEF-Ocugen Provides Update INDA With U.S. FDA To Initiate Phase 3 Trial Evaluating Covid-19 Vaccine Candidate Covaxin

    Reuters – 7:04 AM ET 11/26/2021

    Ocugen Inc (OCGN): * OCUGEN, INC. PROVIDES AN UPDATE ON ITS INVESTIGATIONAL NEW DRUG APPLICATION WITH U.S. FDA TO INITIATE A PHASE 3 CLINICAL TRIAL EVALUATING COVID-19 VACCINE CANDIDATE COVAXIN™. * Ocugen Inc (OCGN) - FDA PLANS TO IDENTIFY SPECIFIC DEFICIENCIES THAT ARE BASIS FOR CLINICAL HOLD AND INFORMATION ON HOW TO ADDRESS THOSE DEFICIENCIES.

  16. Show article details.

    Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

    GlobeNewswire – 7:01 AM ET 11/26/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration has issued a clinical hold on the Company’s Investigational New Drug application to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States.

  17. Show article details.

    Bharat's COVID-19 shot 50% effective at height of India infections - small study

    Reuters – 1:58 AM ET 11/24/2021

    Bharat Biotech's vaccine was only 50% effective at preventing symptomatic COVID-19 in a high-risk population during a devastating second wave of infections in India this year, data gleaned from hospital workers showed.

  18. Show article details.

    Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:03 PM ET 11/18/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen (OCGN) approved the grant of stock options to purchase an aggregate of 93,000 shares of its common stock and restricted stock unit...

  19. Show article details.

    BRIEF-Ocugen Provides Third Quarter 2021 Financial Results

    Reuters – 7:41 AM ET 11/09/2021

    Ocugen Inc (OCGN): * Q3 LOSS PER SHARE $0.05 Source text for Eikon: Further company coverage:

  20. Show article details.

    Ocugen Provides Business Update and Third Quarter 2021 Financial Results

    GlobeNewswire – 7:30 AM ET 11/09/2021

    Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., Nov. 09, 2021 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported third quarter 2021 financial results along with a general business update.

Page:

Today's and Upcoming Events

  • Mar
    16

    OCGN to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    09

    OCGN announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.